| Authors: |
Vallortigara J; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom., Greenfield J; Ataxia UK, London, United Kingdom., Hunt B; Ataxia UK, London, United Kingdom., Schuman BJ; Friedreich Ataxie Förderverein e.V., Pliening, Germany., Hoffman D; Takeda Pharmaceuticals, Cambridge, MA, United States., Booth S; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom., Reinhard C; Centre for Rare Diseases and Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany., Graessner H; Centre for Rare Diseases and Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany., Federico A; Department of Medicine, Surgery and Neurosciences, Medical School, University of Siena, Italy., Quoidbach V; European Brain Council, Brussels, Belgium., Morris S; Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom., Giunti P; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom. |
